Share Price and Basic Stock Data
Last Updated: February 2, 2026, 4:23 pm
| PEG Ratio | -241.65 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Sakar Healthcare Ltd operates within the Hospitals & Medical Services sector, recording a current share price of ₹383 and a market capitalization of ₹852 Cr. The company’s revenue has shown a steady increase, with sales rising from ₹128 Cr in March 2022 to ₹133 Cr in March 2023, and projected to reach ₹153 Cr in March 2024, followed by ₹178 Cr in March 2025. Quarterly sales figures demonstrate this upward trend, with a notable increase from ₹30.71 Cr in September 2022 to ₹40.65 Cr in March 2023. However, subsequent quarters indicate fluctuations, with sales reported at ₹34.08 Cr in September 2023 and ₹37.23 Cr in December 2023. The trailing twelve-month (TTM) sales stand at ₹204 Cr, reflecting a robust growth trajectory. This revenue growth is essential for sustaining operations and enhancing market positioning amidst increasing competition in the healthcare sector.
Profitability and Efficiency Metrics
Sakar Healthcare’s profitability ratios indicate a mixed performance. The company’s operating profit margin (OPM) stood at 19.74%, demonstrating a consistent ability to manage operational costs effectively. However, the OPM has varied over the quarters, peaking at 31.29% in March 2025 before declining to 19.74% in September 2025. Net profit for the company was reported at ₹20 Cr, translating to a net profit margin of 9.85% for the fiscal year 2025. The return on equity (ROE) was recorded at 6.48%, while return on capital employed (ROCE) stood at 8.54%, both of which are relatively low compared to sector averages, suggesting room for improvement in capital efficiency. Additionally, the interest coverage ratio (ICR) of 5.98x indicates a healthy capacity to meet interest obligations, although the declining trend in profitability metrics raises concerns about long-term sustainability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Sakar Healthcare reveals a total borrowing of ₹72 Cr against reserves of ₹281 Cr, indicating a manageable debt level and a strong equity base. The company reported a debt-to-equity ratio of 0.26x, which is favorable compared to typical industry standards, suggesting prudent financial management. The current ratio of 1.40x indicates sufficient liquidity to cover short-term obligations. However, the cash conversion cycle (CCC) of 163 days raises concerns about working capital efficiency, as prolonged cycles can strain liquidity. The price-to-book value (P/BV) ratio stands at 1.63x, reflecting a moderate valuation compared to the intrinsic value of the company’s assets. Additionally, the enterprise value (EV) of ₹539.37 Cr, combined with its net operating revenue, suggests that while the company is growing, it may also be overvalued relative to its earnings potential.
Shareholding Pattern and Investor Confidence
Sakar Healthcare’s shareholding structure illustrates a significant promoter holding of 52.86% as of September 2025, indicating strong insider confidence in the company’s prospects. Foreign institutional investors (FIIs) hold 13.31%, while domestic institutional investors (DIIs) account for 11.43%, reflecting a balanced interest from both domestic and foreign investors. The public shareholding stands at 22.41%, with a total of 7,565 shareholders. Notably, promoter holdings have decreased from 62.10% in December 2022 to the current level, which may indicate dilution of control or strategic adjustments. The gradual increase in DII participation from 0.33% in December 2022 to 11.43% in September 2025 signals growing institutional confidence. This evolving shareholding pattern may positively influence market perception, although the declining promoter stake could raise concerns about long-term governance and control.
Outlook, Risks, and Final Insight
The outlook for Sakar Healthcare appears cautiously optimistic, supported by revenue growth and a strong balance sheet. However, several risks persist, including fluctuating profitability margins and a prolonged cash conversion cycle, which could impact liquidity. The company’s ability to enhance operational efficiency and manage costs effectively will be crucial in maintaining profitability. Additionally, external factors such as regulatory changes and competitive pressures in the healthcare sector could influence performance. If Sakar Healthcare can navigate these challenges while leveraging its strong market position and improving operational efficiencies, it stands a good chance of delivering sustained growth. Conversely, failure to address these risks may lead to a decline in investor confidence and market performance.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 45.6 Cr. | 136 | 187/120 | 9.30 | 117 | 2.57 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 15.4 Cr. | 14.6 | 33.0/14.6 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.8 Cr. | 10.4 | 20.5/7.08 | 18.7 | 0.00 % | 3.00 % | 0.81 % | 10.0 | |
| Fortis Malar Hospitals Ltd | 103 Cr. | 54.9 | 98.7/52.2 | 22.7 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 18.6 Cr. | 3.44 | 6.42/3.28 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 24,559.00 Cr | 660.97 | 83.15 | 92.86 | 0.36% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30.71 | 33.47 | 40.65 | 38.99 | 34.08 | 37.23 | 43.06 | 41.15 | 42.78 | 43.42 | 50.24 | 52.74 | 57.56 |
| Expenses | 22.12 | 24.67 | 32.87 | 29.96 | 24.72 | 28.22 | 32.09 | 30.45 | 31.28 | 31.66 | 34.52 | 40.03 | 46.20 |
| Operating Profit | 8.59 | 8.80 | 7.78 | 9.03 | 9.36 | 9.01 | 10.97 | 10.70 | 11.50 | 11.76 | 15.72 | 12.71 | 11.36 |
| OPM % | 27.97% | 26.29% | 19.14% | 23.16% | 27.46% | 24.20% | 25.48% | 26.00% | 26.88% | 27.08% | 31.29% | 24.10% | 19.74% |
| Other Income | 0.60 | 1.85 | 1.81 | 1.52 | 0.66 | 0.23 | 0.77 | 0.46 | 0.37 | 0.25 | 0.18 | 0.39 | 1.21 |
| Interest | 0.99 | 1.94 | 2.15 | 2.08 | 1.65 | 1.79 | 2.08 | 1.40 | 1.64 | 1.30 | 4.19 | 2.14 | 1.53 |
| Depreciation | 3.77 | 4.10 | 3.55 | 4.52 | 4.22 | 4.44 | 4.87 | 5.06 | 5.12 | 5.23 | 5.48 | 5.57 | 5.68 |
| Profit before tax | 4.43 | 4.61 | 3.89 | 3.95 | 4.15 | 3.01 | 4.79 | 4.70 | 5.11 | 5.48 | 6.23 | 5.39 | 5.36 |
| Tax % | 56.21% | 13.02% | -0.77% | 28.10% | 12.53% | 30.90% | 34.86% | 48.72% | 6.07% | 17.15% | 7.70% | 13.17% | 15.30% |
| Net Profit | 1.94 | 4.01 | 3.92 | 2.84 | 3.64 | 2.07 | 3.12 | 2.41 | 4.80 | 4.53 | 5.76 | 4.67 | 4.54 |
| EPS in Rs | 1.04 | 2.15 | 2.06 | 1.49 | 1.70 | 0.95 | 1.43 | 1.11 | 2.21 | 2.06 | 2.62 | 2.10 | 2.04 |
Last Updated: December 29, 2025, 7:04 am
Below is a detailed analysis of the quarterly data for Sakar Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 57.56 Cr.. The value appears strong and on an upward trend. It has increased from 52.74 Cr. (Jun 2025) to 57.56 Cr., marking an increase of 4.82 Cr..
- For Expenses, as of Sep 2025, the value is 46.20 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 40.03 Cr. (Jun 2025) to 46.20 Cr., marking an increase of 6.17 Cr..
- For Operating Profit, as of Sep 2025, the value is 11.36 Cr.. The value appears to be declining and may need further review. It has decreased from 12.71 Cr. (Jun 2025) to 11.36 Cr., marking a decrease of 1.35 Cr..
- For OPM %, as of Sep 2025, the value is 19.74%. The value appears to be declining and may need further review. It has decreased from 24.10% (Jun 2025) to 19.74%, marking a decrease of 4.36%.
- For Other Income, as of Sep 2025, the value is 1.21 Cr.. The value appears strong and on an upward trend. It has increased from 0.39 Cr. (Jun 2025) to 1.21 Cr., marking an increase of 0.82 Cr..
- For Interest, as of Sep 2025, the value is 1.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 2.14 Cr. (Jun 2025) to 1.53 Cr., marking a decrease of 0.61 Cr..
- For Depreciation, as of Sep 2025, the value is 5.68 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.57 Cr. (Jun 2025) to 5.68 Cr., marking an increase of 0.11 Cr..
- For Profit before tax, as of Sep 2025, the value is 5.36 Cr.. The value appears to be declining and may need further review. It has decreased from 5.39 Cr. (Jun 2025) to 5.36 Cr., marking a decrease of 0.03 Cr..
- For Tax %, as of Sep 2025, the value is 15.30%. The value appears to be increasing, which may not be favorable. It has increased from 13.17% (Jun 2025) to 15.30%, marking an increase of 2.13%.
- For Net Profit, as of Sep 2025, the value is 4.54 Cr.. The value appears to be declining and may need further review. It has decreased from 4.67 Cr. (Jun 2025) to 4.54 Cr., marking a decrease of 0.13 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.04. The value appears to be declining and may need further review. It has decreased from 2.10 (Jun 2025) to 2.04, marking a decrease of 0.06.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:42 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 30 | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 178 | 204 |
| Expenses | 22 | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 128 | 152 |
| Operating Profit | 8 | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 50 | 52 |
| OPM % | 26% | 22% | 20% | 23% | 24% | 25% | 24% | 24% | 23% | 25% | 25% | 28% | 25% |
| Other Income | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 1 | 2 |
| Interest | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 9 | 9 |
| Depreciation | 2 | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 21 | 22 |
| Profit before tax | 2 | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 22 | 22 |
| Tax % | 13% | 24% | 22% | 30% | 38% | 28% | 21% | 19% | 20% | 24% | 27% | 19% | |
| Net Profit | 2 | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 18 | 20 |
| EPS in Rs | 2.19 | 2.30 | 2.78 | 3.08 | 3.12 | 4.47 | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 7.97 | 8.82 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | 0.00% | 50.00% | 33.33% | 75.00% | 42.86% | 10.00% | 36.36% | -13.33% | -7.69% | 50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 50.00% | -16.67% | 41.67% | -32.14% | -32.86% | 26.36% | -49.70% | 5.64% | 57.69% |
Sakar Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 16% |
| 3 Years: | 11% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 13% |
| 3 Years: | 5% |
| TTM: | 76% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 13% |
| 1 Year: | 6% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 6% |
Last Updated: September 5, 2025, 1:15 pm
Balance Sheet
Last Updated: January 7, 2026, 4:20 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 | 22 |
| Reserves | 6 | 7 | 11 | 25 | 39 | 57 | 66 | 83 | 110 | 154 | 241 | 264 | 281 |
| Borrowings | 24 | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 86 | 72 |
| Other Liabilities | 14 | 11 | 10 | 11 | 18 | 15 | 17 | 37 | 47 | 44 | 47 | 43 | 73 |
| Total Liabilities | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 449 |
| Fixed Assets | 38 | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 309 | 325 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 17 | 17 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 | 0 |
| Other Assets | 14 | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 90 | 107 |
| Total Assets | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 | 449 |
Below is a detailed analysis of the balance sheet data for Sakar Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is 281.00 Cr.. The value appears strong and on an upward trend. It has increased from 264.00 Cr. (Mar 2025) to 281.00 Cr., marking an increase of 17.00 Cr..
- For Borrowings, as of Sep 2025, the value is 72.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 86.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 14.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 73.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2025) to 73.00 Cr., marking an increase of 30.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 449.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 415.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 34.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 325.00 Cr.. The value appears strong and on an upward trend. It has increased from 309.00 Cr. (Mar 2025) to 325.00 Cr., marking an increase of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 107.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Mar 2025) to 107.00 Cr., marking an increase of 17.00 Cr..
- For Total Assets, as of Sep 2025, the value is 449.00 Cr.. The value appears strong and on an upward trend. It has increased from 415.00 Cr. (Mar 2025) to 449.00 Cr., marking an increase of 34.00 Cr..
Notably, the Reserves (281.00 Cr.) exceed the Borrowings (72.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -16.00 | -17.00 | -14.00 | -14.00 | 2.00 | 6.00 | 3.00 | -20.00 | -64.00 | -86.00 | -41.00 | -36.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28 | 21 | 26 | 44 | 74 | 51 | 36 | 48 | 40 | 60 | 50 | 63 |
| Inventory Days | 190 | 142 | 107 | 114 | 51 | 70 | 92 | 112 | 69 | 76 | 121 | 193 |
| Days Payable | 97 | 20 | 66 | 51 | 57 | 41 | 46 | 141 | 149 | 129 | 120 | 93 |
| Cash Conversion Cycle | 120 | 143 | 67 | 107 | 68 | 80 | 83 | 19 | -39 | 7 | 51 | 163 |
| Working Capital Days | -8 | 27 | 10 | 67 | 98 | 31 | 31 | 2 | -11 | -6 | 29 | 52 |
| ROCE % | 15% | 14% | 14% | 15% | 14% | 16% | 16% | 13% | 12% | 9% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 7.97 | 5.63 | 6.75 | 8.73 | 6.84 |
| Diluted EPS (Rs.) | 7.95 | 5.63 | 6.75 | 8.73 | 6.84 |
| Cash EPS (Rs.) | 17.49 | 13.66 | 14.57 | 14.52 | 12.00 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 130.06 | 120.61 | 91.04 | 74.46 | 63.04 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 130.06 | 120.61 | 91.04 | 74.46 | 63.04 |
| Revenue From Operations / Share (Rs.) | 80.90 | 70.51 | 70.04 | 74.91 | 60.66 |
| PBDIT / Share (Rs.) | 23.23 | 19.10 | 19.86 | 18.40 | 15.22 |
| PBIT / Share (Rs.) | 13.72 | 10.80 | 11.99 | 12.75 | 10.06 |
| PBT / Share (Rs.) | 9.81 | 7.31 | 8.87 | 11.06 | 8.47 |
| Net Profit / Share (Rs.) | 7.97 | 5.37 | 6.70 | 8.87 | 6.84 |
| NP After MI And SOA / Share (Rs.) | 7.97 | 5.37 | 6.70 | 8.87 | 6.84 |
| PBDIT Margin (%) | 28.71 | 27.08 | 28.35 | 24.56 | 25.09 |
| PBIT Margin (%) | 16.95 | 15.31 | 17.11 | 17.02 | 16.58 |
| PBT Margin (%) | 12.12 | 10.36 | 12.65 | 14.76 | 13.96 |
| Net Profit Margin (%) | 9.85 | 7.61 | 9.56 | 11.83 | 11.27 |
| NP After MI And SOA Margin (%) | 9.85 | 7.61 | 9.56 | 11.83 | 11.27 |
| Return on Networth / Equity (%) | 6.13 | 4.44 | 7.36 | 11.90 | 10.85 |
| Return on Capital Employeed (%) | 8.55 | 7.12 | 8.10 | 9.87 | 10.87 |
| Return On Assets (%) | 4.21 | 3.00 | 3.79 | 5.66 | 6.00 |
| Long Term Debt / Equity (X) | 0.18 | 0.20 | 0.56 | 0.66 | 0.39 |
| Total Debt / Equity (X) | 0.26 | 0.26 | 0.64 | 0.70 | 0.40 |
| Asset Turnover Ratio (%) | 0.44 | 0.42 | 0.44 | 0.57 | 0.64 |
| Current Ratio (X) | 1.40 | 1.21 | 1.03 | 1.07 | 1.01 |
| Quick Ratio (X) | 0.71 | 0.74 | 0.74 | 0.76 | 0.54 |
| Inventory Turnover Ratio (X) | 4.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.98 | 5.47 | 6.36 | 10.87 | 9.58 |
| Interest Coverage Ratio (Post Tax) (X) | 3.06 | 2.54 | 3.15 | 6.24 | 5.30 |
| Enterprise Value (Cr.) | 539.37 | 869.42 | 493.09 | 320.85 | 216.70 |
| EV / Net Operating Revenue (X) | 3.04 | 5.67 | 3.70 | 2.50 | 2.29 |
| EV / EBITDA (X) | 10.58 | 20.93 | 13.04 | 10.19 | 9.12 |
| MarketCap / Net Operating Revenue (X) | 2.62 | 5.22 | 2.86 | 1.80 | 1.86 |
| Price / BV (X) | 1.63 | 3.05 | 2.20 | 1.81 | 1.79 |
| Price / Net Operating Revenue (X) | 2.62 | 5.22 | 2.86 | 1.80 | 1.86 |
| EarningsYield | 0.03 | 0.01 | 0.03 | 0.06 | 0.06 |
After reviewing the key financial ratios for Sakar Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.97, marking an increase of 2.34.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.95. This value is within the healthy range. It has increased from 5.63 (Mar 24) to 7.95, marking an increase of 2.32.
- For Cash EPS (Rs.), as of Mar 25, the value is 17.49. This value is within the healthy range. It has increased from 13.66 (Mar 24) to 17.49, marking an increase of 3.83.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 130.06. It has increased from 120.61 (Mar 24) to 130.06, marking an increase of 9.45.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 80.90. It has increased from 70.51 (Mar 24) to 80.90, marking an increase of 10.39.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 23.23. This value is within the healthy range. It has increased from 19.10 (Mar 24) to 23.23, marking an increase of 4.13.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.72. This value is within the healthy range. It has increased from 10.80 (Mar 24) to 13.72, marking an increase of 2.92.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 7.31 (Mar 24) to 9.81, marking an increase of 2.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.97. This value is within the healthy range. It has increased from 5.37 (Mar 24) to 7.97, marking an increase of 2.60.
- For PBDIT Margin (%), as of Mar 25, the value is 28.71. This value is within the healthy range. It has increased from 27.08 (Mar 24) to 28.71, marking an increase of 1.63.
- For PBIT Margin (%), as of Mar 25, the value is 16.95. This value is within the healthy range. It has increased from 15.31 (Mar 24) to 16.95, marking an increase of 1.64.
- For PBT Margin (%), as of Mar 25, the value is 12.12. This value is within the healthy range. It has increased from 10.36 (Mar 24) to 12.12, marking an increase of 1.76.
- For Net Profit Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.85. This value is within the healthy range. It has increased from 7.61 (Mar 24) to 9.85, marking an increase of 2.24.
- For Return on Networth / Equity (%), as of Mar 25, the value is 6.13. This value is below the healthy minimum of 15. It has increased from 4.44 (Mar 24) to 6.13, marking an increase of 1.69.
- For Return on Capital Employeed (%), as of Mar 25, the value is 8.55. This value is below the healthy minimum of 10. It has increased from 7.12 (Mar 24) to 8.55, marking an increase of 1.43.
- For Return On Assets (%), as of Mar 25, the value is 4.21. This value is below the healthy minimum of 5. It has increased from 3.00 (Mar 24) to 4.21, marking an increase of 1.21.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 0.2. It has decreased from 0.20 (Mar 24) to 0.18, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.26. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.26.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.44. It has increased from 0.42 (Mar 24) to 0.44, marking an increase of 0.02.
- For Current Ratio (X), as of Mar 25, the value is 1.40. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.40, marking an increase of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.98. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 4.98, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 5.98, marking an increase of 0.51.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.06. This value is within the healthy range. It has increased from 2.54 (Mar 24) to 3.06, marking an increase of 0.52.
- For Enterprise Value (Cr.), as of Mar 25, the value is 539.37. It has decreased from 869.42 (Mar 24) to 539.37, marking a decrease of 330.05.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.04. This value exceeds the healthy maximum of 3. It has decreased from 5.67 (Mar 24) to 3.04, marking a decrease of 2.63.
- For EV / EBITDA (X), as of Mar 25, the value is 10.58. This value is within the healthy range. It has decreased from 20.93 (Mar 24) to 10.58, marking a decrease of 10.35.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
- For Price / BV (X), as of Mar 25, the value is 1.63. This value is within the healthy range. It has decreased from 3.05 (Mar 24) to 1.63, marking a decrease of 1.42.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.62. This value is within the healthy range. It has decreased from 5.22 (Mar 24) to 2.62, marking a decrease of 2.60.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.03, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sakar Healthcare Ltd:
- Net Profit Margin: 9.85%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 8.55% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 6.13% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.71
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 43.6 (Industry average Stock P/E: 83.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.26
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.85%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Block No. 10/13, Village: Changodar, Ahmedabad District Gujarat 382213 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay S Shah | Chairman & Managing Director |
| Mr. Aarsh S Shah | Joint Managing Director |
| Mr. Sunil Marathe | Whole Time Director - Technical |
| Ms. Vishalakshi Chandramouli | Non Executive Director |
| Ms. Rita S Shah | Non Executive Director |
| Mr. Hemendra C Shah | Independent Director |
| Mr. Shailesh B Patel | Independent Director |
| Mr. Prashant C Srivastav | Independent Director |
| Mr. Jignesh Parikh | Independent Director |
| Mrs. Khyati Shah | Independent Director |
| Ms. Megha Samdani | Independent Director |
| Ms. Reeya Kothari | Independent Director |
| Ms. Hiral Patel | Independent Director |
FAQ
What is the intrinsic value of Sakar Healthcare Ltd?
Sakar Healthcare Ltd's intrinsic value (as of 05 February 2026) is ₹312.97 which is 18.28% lower the current market price of ₹383.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹852 Cr. market cap, FY2025-2026 high/low of ₹444/210, reserves of ₹281 Cr, and liabilities of ₹449 Cr.
What is the Market Cap of Sakar Healthcare Ltd?
The Market Cap of Sakar Healthcare Ltd is 852 Cr..
What is the current Stock Price of Sakar Healthcare Ltd as on 05 February 2026?
The current stock price of Sakar Healthcare Ltd as on 05 February 2026 is ₹383.
What is the High / Low of Sakar Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Sakar Healthcare Ltd stocks is ₹444/210.
What is the Stock P/E of Sakar Healthcare Ltd?
The Stock P/E of Sakar Healthcare Ltd is 43.6.
What is the Book Value of Sakar Healthcare Ltd?
The Book Value of Sakar Healthcare Ltd is 136.
What is the Dividend Yield of Sakar Healthcare Ltd?
The Dividend Yield of Sakar Healthcare Ltd is 0.00 %.
What is the ROCE of Sakar Healthcare Ltd?
The ROCE of Sakar Healthcare Ltd is 8.54 %.
What is the ROE of Sakar Healthcare Ltd?
The ROE of Sakar Healthcare Ltd is 6.48 %.
What is the Face Value of Sakar Healthcare Ltd?
The Face Value of Sakar Healthcare Ltd is 10.0.